Trial Profile
A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Resiniferatoxin (Primary) ; Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Registrational
- Sponsors Sorrento Therapeutics
- 14 Mar 2024 Planned initiation date changed from 1 Sep 2023 to 1 Sep 2025.
- 14 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
- 14 Mar 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2027.